Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Driving Menarini's Future With Decisive Steps

CEO Outlines Strategy And Focus On Oncology

Executive Summary

Two years into her tenure as the head of Menarini, Elcin Barker Ergun has already inked two major cancer deals with the acquisition of Stemline and a key licensing pact with Radius Health. The future for the Italian group is bright, she explained to Scrip in an exclusive interview.

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the prospects for Merck’s Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma’s president.

Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy

Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.

Elzonris: A Case Study In Divergent Regulatory Decisions

Stemline Therapeutics’ Elzonris was approved for a rare cancer in Europe in January, following a long and arduous two-year journey through the EU regulatory process that included an initial rejection and a subsequent re-examination by the EMA. Its fortunes were very different in the US, where the review took just six months from filing to approval.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel